A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Lipika,Goyal

第一单位： Harvard Medical School, Boston, MA, USA.;Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, 02114, MA, USA.

作者： Lipika,Goyal ^[1] ; Surendra Pal,Chaudhary ^[2] ; Eunice L,Kwak ^[1] ; Thomas A,Abrams ^[3] ; Amanda N,Carpenter ^[4] ; Brian M,Wolpin ^[3] ; Raymond C,Wadlow ^[5] ; Jill N,Allen ^[1] ; Rebecca,Heist ^[1] ; Nadine Jackson,McCleary ^[3] ; Jennifer A,Chan ^[3] ; Wolfram,Goessling ^[3] ; Deborah,Schrag ^[3] ; Kimmie,Ng ^[3] ; Peter C,Enzinger ^[3] ; David P,Ryan ^[1] ; Jeffrey W,Clark ^[1]

作者单位： Harvard Medical School, Boston, MA, USA.;Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, 02114, MA, USA. ^[1] Harvard Medical School, Boston, MA, USA. Schaudhary1@mgh.harvard.edu.;Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, 02114, MA, USA. Schaudhary1@mgh.harvard.edu. ^[2] Harvard Medical School, Boston, MA, USA.;Dana Farber Cancer Institute, Boston, MA, USA. ^[3] Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, 02114, MA, USA. ^[4] Virginia Cancer Specialist, Fairfax, VA, USA. ^[5]

关键词 Clinical trial Esophagogastric cancer HER2 Heat shock protein Phase II